Chairman of the board
Born 1953. Chairman of the board since 2020.
Education and experience: Thomas holds a M.D. from Karolinska Institutet and a Ph.D. in Medicine from Uppsala University. He was previously CEO of Global Medical Investments and is a former partner of venture capital firm 3i. He also held VP roles at Pharmacia Corp. and Schering-Plough Inc. He was responsible for market approval of several pharmaceutical products in various therapeutic areas that have generated billions in annual sales. Thomas has international board experience in major corporations as well as start-ups and venture investing.
Acting Chief Financial Officer
Born 1966. Acting CFO since 2022. Board Member since 2021.
Education and experience: Cecilia has a B.Sc. at Stockholm School of Economics. Cecilia has extensive experience of operational work in senior positions in several industries. She is Senior Advisor and board member of Bactiguard, a Swedish company with a focus on infection prevention. She has previously held various roles in the company, including as CEO and CFO with responsibility for business development, and thus has good insight into specific issues in urology and medical technology in an international market.
Born 1954. Board member since 2021.
Education and experience: Eugen is a medical doctor and earned his M.D. and Ph.D. in Clinical Pharmacology from Karolinska Institutet. He has over 30 years of experience from CEO and board assignments in several Swedish, Norwegian, UK and US life-science companies in various development phases. He has been a venture partner at HealthCap since 1997.
Born 1961. Board member since 2021.
Education and experience: Henrik has a M.D. and Ph.D. in Oncology at Umeå University. Henrik is a professor of cancer epidemiology at Karolinska Institutet, where he leads a research group with 35 researchers focused on prostate cancer. Henrik is a co-founder of A3P Biomedical, one of the company’s largest owners and a leading expert in prostate cancer.
Born 1966. Board member since 2022.
Education and experience: Mark Quick is a partner in Flerie which invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. Prior to Flerie, Mark Quick was responsible for Recipharm’s M&A operations and was part of the company management. Before that he spent time at ICI, Medeva, Celltech and UCB in various business development and supply chain roles. He also has an MBA from The Open University.
Board Member & Vice President Corporate Development
Born 1969. Board member since 2020.
Education and experience: Martin holds an MBA at the Stockholm School of Economics. He is the co-founder of A3P Biomedical AB and one of the company’s largest owners. Martin has more than 15 years’ experience of working in interface between academia and industry. His former positions include Investment Manager with the venture capital firm Litorina Kapital and Manager with Arthur D. Little.